Lilly’s amylin agonist delivers up to 20% weight loss in mid-stage trial

[Indianapolis - April 2016: Eli Lilly and Company VII]
jetcityimage/iStock Editorial via Getty Images

Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]) said on Thursday that eloralintide, its experimental amylin receptor agonist for obesity, helped patients lose up to 20% of their weight in a mid-stage trial involving obese or overweight people without diabetes.

Based on a per-protocol analysis of data from a Phase 2 trial for the once-weekly injectable, the Indiana-based drugmaker said eloralintide caused average weight reductions from 9.5% to 20.1%, while the placebo group experienced an average weight loss of 0.4%.

The 48-week trial enrolled 263 obese or overweight patients with one or more weight-related conditions but without type 2 diabetes. As its primary objective, the U.S.-based study was designed to evaluate eloralintide’s superiority against placebo in causing percentage body weight reduction.

Regarding safety, the maker of Zepbound weight-loss therapy said that mild to moderate gastrointestinal symptoms and fatigue were the most common adverse events linked to eloralintide.

The company expects to advance eloralintide into Phase 3 development later this year to evaluate it as a single agent for obesity. The data readout was published in The Lancet and also presented at the ongoing ObesityWeek 2025 in Atlanta, GA. [https://seekingalpha.com/pr/20296214-lillys-selective-amylin-agonist-eloralintide-demonstrated-meaningful-weight-loss-and]

MORE ON ELI LILLY

* Eli Lilly Has A Solid Upside Now After Its Q3 Earnings [https://seekingalpha.com/article/4836307-eli-lilly-has-a-solid-upside-now-after-its-q3-earnings]
* Eli Lilly: The Price Upside Just Increased [https://seekingalpha.com/article/4835836-eli-lilly-the-price-upside-just-increased]
* Eli Lilly and Company (LLY) Q3 2025 Earnings Call Transcript [https://seekingalpha.com/article/4835587-eli-lilly-and-company-lly-q3-2025-earnings-call-transcript]
* Eli Lilly, Novo reportedly nearing U.S. deals for obesity drug prices (update) [https://seekingalpha.com/news/4514411-eli-lilly-novo-us-deals-obesity-drug-prices]
* Eli Lilly to invest in a $3B manufacturing facility in Netherlands [https://seekingalpha.com/news/4512936-eli-lilly-to-invest-in-a-3b-manufacturing-facility-in-netherlands]